49119No. (n = 422)15826451 (12–89)302120884939113311693924755412073/2331774/44/19/13/534/8/726/16/412/11/10/73915/13/7/335Characteristic表1 IMPACTコホートの患者背景Sex Male FemaleMedian age at the start of therapy, y (range)Age groups <65-y >=65-yDisease Rheumatic diseases Rheumatoid arthritis and its related diseases Spondyloarthritis and its related diseases Systemic lupus erythematosus and its related diseases Bechet’s disease Familial mediterranean fever Cutaneous polyarteritis nodosa IgG4-related disease Sarcoid arthritis Inflammatory bowel diseases Crohn’s disease Ulcerative colitis Others Inflammatory skin diseases Psoriasis Hidradenitis suppurativa Palmoplantar pustulosis Generalized pustular psoriasis Perifolliculitis capitis abscedens et suffodiens Malignant diseases Melanoma Cervical cancer MSI-high/TMB-high cancer Extramammary paget’s disease Cutaneous squamous cell carcinoma Other diseasesTherapeutic monoclonal antibody Anti–TNF-α Infliximab/Golimumab/Adalimumab/Certolizumab pegol/ Ozoralizumab Anti–IL-6R Sarilumab/Satralizumab/Tocilizumab Anti–IL-23 p19 Risankizumab/Guserukumab/Tildrakizumab Anti–IL-17 Ixekizumab/Brodalumab/Secukinumab/Bimekizumab Anti–IL-12/23 p40 Ustekinumab Anti–PD-1 or anti–PD-1/CTLA-4 Nivolumab/Pembrolizumab/Cemiplimab/Nivolumab + Ipilimumab Anti–BLyS Belimumab Anti–α4β7-integrin Vedolizumab Anti–CD19 Inebilizumab Anti–IL-36R Spesolimab OthersAbbreviations: MSI, microsatellite instability; TMB, tumor mutational burden
元のページ ../index.html#18